1. Adachi, Y., Kas, E. and Laemmli, U. (1989). Preferential, cooperative binding of topoisomerase II to scaffold-associated regions. EMBO Jl, 8, 3997–4006
2. Baguley, B. C. (1991). DNA intercalating anti-tumour agents. Anti-cancer Drug Des., 6, 1–35
3. Baguley, B. C., Holdaway, K. M. and Fray, L. M. (1990). Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J. Natl Cancer Inst., 82, 399–402
4. Bailly, C., Bernier, J. L., Houssin, R., Helbecque, N. and Hénichart, J. P. (1987). Design of two metal-chelating, DNA-binding models: molecular combinations of bleomycin and amsacrine anti-tumour drugs. Anti-cancer Drug Des., 1, 303–312
5. Bailly, C., Catteau, J. P., Hénichart, J. P., Reszka, K., Shea, R. G., Krowicki, K. and Lown, J. W. (1989a). Subcellular distribution of a nitroxide spin-labeled netropsin in living KB cells. Biochem. Pharmacol., 38, 1625–1630